leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals acquires Canadian rights to therapies for Dry Eye

Aequus Pharmaceuticals (CVE:AQS-OTCQB-) Chairman and CEO Doug Janzen sat down with Steve Darling from Proactive Investors Vancouver to discuss the company acquiring the Canadian rights to a line of products that help people deal with Dry Eye. 

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.105 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $11.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Scout Security signs strategic agreement with large full-service telecom...

Scout Security Limited (ASX: SCT) CEO Dan Roberts joined Steve Darling from Proactive with news the company has expanded its white label program with the signing of a master services agreement with Windstream Services. That company has 1.3 million household telecommunications subscribers in...

3 hours, 23 minutes ago

2 min read